Welcome to LookChem.com Sign In|Join Free

CAS

  • or
(S)-2-AMINO-3-(3,4-DIHYDROXY-PHENYL)-PROPIONIC ACID METHYL ESTER, also known as CHF-1301, is a prodrug of L-Dopa (levodopa), the immediate precursor of dopamine. It is more soluble in water at physiological pH, better absorbed, and slowly transformed into levodopa in vivo, improving the duration of action and preventing rapid fluctuations in response or involuntary movements (dyskinesia) observed during chronic treatment with levodopa.
Used in Pharmaceutical Industry:
CHF-1301 is used as a treatment for patients with Parkinson's disease, particularly those with complications in their clinical responses. It is particularly effective in patients with a delayed effect of levodopa (on-phenomenon) or severe resistance to L-Dopa (off-phenomenon), significantly improving the onset and stability of the response.

7101-51-1 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 7101-51-1 Structure
  • Basic information

    1. Product Name: (S)-2-AMINO-3-(3,4-DIHYDROXY-PHENYL)-PROPIONIC ACID METHYL ESTER
    2. Synonyms: (S)-2-AMINO-3-(3,4-DIHYDROXY-PHENYL)-PROPIONIC ACID METHYL ESTER;levodopa methyl ester;DOPA-METHYLESTER;L-DOPA Methyl Ester;(S)-2-AMino-3-(3,4-dihydroxy-phenyl)-propionic acid Methyl ester hydrochloride;L-Tyrosine, 3-hydroxy-, Methyl ester;Methyl 3-hydroxy-L-tyrosinate;methyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate
    3. CAS NO:7101-51-1
    4. Molecular Formula: C10H13NO4
    5. Molecular Weight: 211.21452
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 7101-51-1.mol
  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: 350.89°C (rough estimate)
    3. Flash Point: 186.3°C
    4. Appearance: /
    5. Density: 1.2545 (rough estimate)
    6. Vapor Pressure: 1.86E-06mmHg at 25°C
    7. Refractive Index: 1.5150 (estimate)
    8. Storage Temp.: 2-8°C
    9. Solubility: N/A
    10. CAS DataBase Reference: (S)-2-AMINO-3-(3,4-DIHYDROXY-PHENYL)-PROPIONIC ACID METHYL ESTER(CAS DataBase Reference)
    11. NIST Chemistry Reference: (S)-2-AMINO-3-(3,4-DIHYDROXY-PHENYL)-PROPIONIC ACID METHYL ESTER(7101-51-1)
    12. EPA Substance Registry System: (S)-2-AMINO-3-(3,4-DIHYDROXY-PHENYL)-PROPIONIC ACID METHYL ESTER(7101-51-1)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 7101-51-1(Hazardous Substances Data)

7101-51-1 Usage

Originator

Chiesi Farmaceutici SpA (Italy)

Check Digit Verification of cas no

The CAS Registry Mumber 7101-51-1 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 7,1,0 and 1 respectively; the second part has 2 digits, 5 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 7101-51:
(6*7)+(5*1)+(4*0)+(3*1)+(2*5)+(1*1)=61
61 % 10 = 1
So 7101-51-1 is a valid CAS Registry Number.
InChI:InChI=1/C10H13NO4/c1-15-10(14)7(11)4-6-2-3-8(12)9(13)5-6/h2-3,5,7,12-13H,4,11H2,1H3/t7-/m0/s1

7101-51-1SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name methyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate

1.2 Other means of identification

Product number -
Other names 3-Hydroxy-L-tyrosine methyl ester

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:7101-51-1 SDS

7101-51-1Synthetic route

methanol
67-56-1

methanol

levodopa
59-92-7

levodopa

L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

Conditions
ConditionsYield
With thionyl chloride at 0 - 20℃; Inert atmosphere;100%
With thionyl chloride Reflux;90%
With hydrogenchloride
L-Tyr-OMe
1080-06-4

L-Tyr-OMe

L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

Conditions
ConditionsYield
With 1,3,6,8-tetra-n-butylpyrimido<5,4-g>pteridine-2,4,5,7(1H,3H,6H,8H)-tetrone 10-oxide In acetonitrile for 0.666667h; Irradiation;25%
(+/-)-3-(3,4-dihydroxyphenyl)-2-methyl-DL-alanine
7101-51-1, 41439-83-2, 71855-43-1

(+/-)-3-(3,4-dihydroxyphenyl)-2-methyl-DL-alanine

A

levodopa
59-92-7

levodopa

B

L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

C

(R)-(3,4-dihydroxyphenyl)alanine methyl ester
71855-43-1

(R)-(3,4-dihydroxyphenyl)alanine methyl ester

Conditions
ConditionsYield
With Alcalase; water In tert-butyl alcohol at 25℃; for 2.5h; pH=8.5; kinetic resolution; Title compound not separated from byproducts;
N-[(phenylmethoxy)carbonyl]-3-hydroxy-O-(phenylmethyl)-L-tyrosine methyl ester
105229-41-2

N-[(phenylmethoxy)carbonyl]-3-hydroxy-O-(phenylmethyl)-L-tyrosine methyl ester

L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

Conditions
ConditionsYield
With hydrogen; palladium on activated charcoal In dichloromethane
(S)-3-(3-Acetoxy-4-benzyloxy-phenyl)-2-benzyloxycarbonylamino-propionic acid methyl ester

(S)-3-(3-Acetoxy-4-benzyloxy-phenyl)-2-benzyloxycarbonylamino-propionic acid methyl ester

L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 453 mg / NH3 / CH2Cl2; methanol / 1 h
2: H2 / Pd/C / CH2Cl2
View Scheme
L-tyrosine
60-18-4

L-tyrosine

L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

Conditions
ConditionsYield
Multi-step reaction with 7 steps
1: 67 percent / AlCl3 / nitrobenzene / 6 h / 100 °C
2: 74 percent / SOCl2 / Heating
3: 93 percent / aq. Na2CO3 / diethyl ether / 3 h / 25 °C
4: 60 percent / K2CO3; (n-Bu)4NI / dimethylformamide / 6 h / 20 °C
5: mCPBA / CH2Cl2 / 40 °C
6: 453 mg / NH3 / CH2Cl2; methanol / 1 h
7: H2 / Pd/C / CH2Cl2
View Scheme
L-3-(3-acetyl-4-hydroxyphenyl)-N-(benzyloxycarbonyl)alanine methyl ester
110774-03-3

L-3-(3-acetyl-4-hydroxyphenyl)-N-(benzyloxycarbonyl)alanine methyl ester

L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: 60 percent / K2CO3; (n-Bu)4NI / dimethylformamide / 6 h / 20 °C
2: mCPBA / CH2Cl2 / 40 °C
3: 453 mg / NH3 / CH2Cl2; methanol / 1 h
4: H2 / Pd/C / CH2Cl2
View Scheme
(S)-3-(3-acetyl-4-hydroxyphenyl)-2-aminopropanoic acid hydrochloride
32404-28-7

(S)-3-(3-acetyl-4-hydroxyphenyl)-2-aminopropanoic acid hydrochloride

L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

Conditions
ConditionsYield
Multi-step reaction with 6 steps
1: 74 percent / SOCl2 / Heating
2: 93 percent / aq. Na2CO3 / diethyl ether / 3 h / 25 °C
3: 60 percent / K2CO3; (n-Bu)4NI / dimethylformamide / 6 h / 20 °C
4: mCPBA / CH2Cl2 / 40 °C
5: 453 mg / NH3 / CH2Cl2; methanol / 1 h
6: H2 / Pd/C / CH2Cl2
View Scheme
methyl (S)-3-(3-acetyl-4-hydroxyphenyl)-2-aminopropanoate monohydrochloride
57085-32-2

methyl (S)-3-(3-acetyl-4-hydroxyphenyl)-2-aminopropanoate monohydrochloride

L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

Conditions
ConditionsYield
Multi-step reaction with 5 steps
1: 93 percent / aq. Na2CO3 / diethyl ether / 3 h / 25 °C
2: 60 percent / K2CO3; (n-Bu)4NI / dimethylformamide / 6 h / 20 °C
3: mCPBA / CH2Cl2 / 40 °C
4: 453 mg / NH3 / CH2Cl2; methanol / 1 h
5: H2 / Pd/C / CH2Cl2
View Scheme
L-3-(3-acetyl-4-(benzyloxy)phenyl)-N-(benzyloxycarbonyl)alanine methyl ester
105205-69-4

L-3-(3-acetyl-4-(benzyloxy)phenyl)-N-(benzyloxycarbonyl)alanine methyl ester

L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: mCPBA / CH2Cl2 / 40 °C
2: 453 mg / NH3 / CH2Cl2; methanol / 1 h
3: H2 / Pd/C / CH2Cl2
View Scheme
levodopa
59-92-7

levodopa

L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

Conditions
ConditionsYield
With thionyl chloride In methanol for 18h;
methyl (S)-2-(tert-butoxycarbonylamino)-3-(3,4-dihydroxyphenyl)propanoate
37169-36-1

methyl (S)-2-(tert-butoxycarbonylamino)-3-(3,4-dihydroxyphenyl)propanoate

L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

Conditions
ConditionsYield
With hydrogenchloride In ethyl acetate
L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

Diethyl ketomalonate
609-09-6

Diethyl ketomalonate

6,7-dihydroxy-3,4-dihydro-2H-isoquinoline-1,1,3-tricarboxylic acid diethyl ester methyl ester

6,7-dihydroxy-3,4-dihydro-2H-isoquinoline-1,1,3-tricarboxylic acid diethyl ester methyl ester

Conditions
ConditionsYield
With trifluoroacetic acid In toluene at 85℃; for 2h; Pictet-Spegler condensation;98%
L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

3,4,5-trimethoxy-benzaldehyde
86-81-7

3,4,5-trimethoxy-benzaldehyde

(1S,3S)-6,7-Dihydroxy-1-(3,4,5-trimethoxy-phenyl)-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid methyl ester
128049-96-7

(1S,3S)-6,7-Dihydroxy-1-(3,4,5-trimethoxy-phenyl)-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid methyl ester

Conditions
ConditionsYield
With sodium acetate In acetic acid for 18h; Ambient temperature;95%
di-tert-butyl dicarbonate
24424-99-5

di-tert-butyl dicarbonate

L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

methyl (S)-2-(tert-butoxycarbonylamino)-3-(3,4-dihydroxyphenyl)propanoate
37169-36-1

methyl (S)-2-(tert-butoxycarbonylamino)-3-(3,4-dihydroxyphenyl)propanoate

Conditions
ConditionsYield
With triethylamine In methanol at 20℃;95%
With sodium hydrogencarbonate In tetrahydrofuran at 0 - 20℃; for 2h; Product distribution / selectivity;90%
With N-ethyl-N,N-diisopropylamine In tetrahydrofuran at 20℃; for 1h;13.4 g
di-tert-butyl dicarbonate
24424-99-5

di-tert-butyl dicarbonate

L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

(S)-(+)-2-tert-butoxycarbonylamino-3-(3,4-dimethoxyphenyl)propionic acid methyl ester
138908-56-2

(S)-(+)-2-tert-butoxycarbonylamino-3-(3,4-dimethoxyphenyl)propionic acid methyl ester

Conditions
ConditionsYield
Stage #1: L-DOPA methyl ester With thionyl chloride In methanol at 50℃; for 3h; Inert atmosphere; Cooling with ice;
Stage #2: di-tert-butyl dicarbonate With sodium hydrogencarbonate In tetrahydrofuran at 20℃; for 1h; Cooling with ice;
Stage #3: With potassium carbonate; dimethyl sulfate In acetone at 20℃; Reflux;
94.4%
L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

(3aR,6R,6aR)-2,2-dimethyl-6-(tosyloxymethyl)-tetrahydro-2H-furo[3,4-d]-1,3-dioxol-4-ol
950182-24-8

(3aR,6R,6aR)-2,2-dimethyl-6-(tosyloxymethyl)-tetrahydro-2H-furo[3,4-d]-1,3-dioxol-4-ol

C18H23NO7
1541171-38-3

C18H23NO7

Conditions
ConditionsYield
In dichloromethane at 20℃; for 10h; Pictet-Spengler Synthesis; Inert atmosphere; diastereoselective reaction;88%
L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

chloroformic acid ethyl ester
541-41-3

chloroformic acid ethyl ester

(S)-3-(3,4-Dihydroxy-phenyl)-2-ethoxycarbonylamino-propionic acid methyl ester
682801-34-9

(S)-3-(3,4-Dihydroxy-phenyl)-2-ethoxycarbonylamino-propionic acid methyl ester

Conditions
ConditionsYield
With iPrEtN In dichloromethane78%
L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

D-lyxose tosylate

D-lyxose tosylate

C18H23NO7
1541171-41-8

C18H23NO7

Conditions
ConditionsYield
In dichloromethane at 20℃; for 47h; Pictet-Spengler Synthesis; Inert atmosphere; diastereoselective reaction;78%
C23H17N3O4
137130-06-4

C23H17N3O4

L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

methyl (2S)-3-(3,4-dihydroxyphenyl)-2-[(2-{3-[4-(1H-3-indolyl)-1-methyl-2,5-dioxo-2,5-dihydro-1H-3-pyrrolyl]-1H-1-indolyl}acetyl)amino]propanoate
1246473-68-6

methyl (2S)-3-(3,4-dihydroxyphenyl)-2-[(2-{3-[4-(1H-3-indolyl)-1-methyl-2,5-dioxo-2,5-dihydro-1H-3-pyrrolyl]-1H-1-indolyl}acetyl)amino]propanoate

Conditions
ConditionsYield
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃;73%
1-pyrenemethanol
24463-15-8

1-pyrenemethanol

L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

1,1'-carbonyldiimidazole
530-62-1

1,1'-carbonyldiimidazole

N-[(pyren-1-yl)methoxycarbonyl]-L-3,4-dihydroxyphenylalanine methyl ester
1251958-98-1

N-[(pyren-1-yl)methoxycarbonyl]-L-3,4-dihydroxyphenylalanine methyl ester

Conditions
ConditionsYield
Stage #1: 1-pyrenemethanol; 1,1'-carbonyldiimidazole In N,N-dimethyl-formamide at 0 - 20℃; for 1h;
Stage #2: L-DOPA methyl ester In N,N-dimethyl-formamide for 12h;
40%
L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

4'-O-demethyl-4β-(4''-carboxyanilino)-4-desoxypodophyllotoxin
152833-18-6

4'-O-demethyl-4β-(4''-carboxyanilino)-4-desoxypodophyllotoxin

(S)-3-(3,4-Dihydroxy-phenyl)-2-{4-[(5S,5aS,8aR,9R)-9-(4-hydroxy-3,5-dimethoxy-phenyl)-8-oxo-5,5a,6,8,8a,9-hexahydro-furo[3',4':6,7]naphtho[2,3-d][1,3]dioxol-5-ylamino]-benzoylamino}-propionic acid methyl ester

(S)-3-(3,4-Dihydroxy-phenyl)-2-{4-[(5S,5aS,8aR,9R)-9-(4-hydroxy-3,5-dimethoxy-phenyl)-8-oxo-5,5a,6,8,8a,9-hexahydro-furo[3',4':6,7]naphtho[2,3-d][1,3]dioxol-5-ylamino]-benzoylamino}-propionic acid methyl ester

Conditions
ConditionsYield
With dmap; dicyclohexyl-carbodiimide In tetrahydrofuran at 20℃;33%
Fmoc-Gly-H

Fmoc-Gly-H

L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

A

(1R,3S)-1-[(N-fluorenyl)methoxycarbonyl]aminomethyl-3-methoxycarbonyl-1,2,3,4-tetrahydro-6,7-dihydroxyisoquinoline

(1R,3S)-1-[(N-fluorenyl)methoxycarbonyl]aminomethyl-3-methoxycarbonyl-1,2,3,4-tetrahydro-6,7-dihydroxyisoquinoline

B

(1S,3S)-1-[(N-fluorenyl)methoxycarbonyl]aminomethyl-3-methoxycarbonyl-1,2,3,4-tetrahydro-6,7-dihydroxyisoquinoline

(1S,3S)-1-[(N-fluorenyl)methoxycarbonyl]aminomethyl-3-methoxycarbonyl-1,2,3,4-tetrahydro-6,7-dihydroxyisoquinoline

C

(1R,3S)-1-[(9H-Fluoren-1-ylmethoxycarbonylamino)-methyl]-7,8-dihydroxy-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid methyl ester

(1R,3S)-1-[(9H-Fluoren-1-ylmethoxycarbonylamino)-methyl]-7,8-dihydroxy-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid methyl ester

D

(1S,3S)-1-[(9H-Fluoren-1-ylmethoxycarbonylamino)-methyl]-7,8-dihydroxy-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid methyl ester

(1S,3S)-1-[(9H-Fluoren-1-ylmethoxycarbonylamino)-methyl]-7,8-dihydroxy-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid methyl ester

Conditions
ConditionsYield
With trifluoroacetic acid In dichloromethane at 20℃; for 6h; Pictet-Spengler condensation;A 29%
B 19%
C n/a
D n/a
Fmoc-Ala-H

Fmoc-Ala-H

L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

A

(1R,3S,1'S)-1-{[1'-(N-fluorenyl)methoxycarbonyl]amino}ethyl-3-methoxycarbonyl-1,2,3,4-tetrahydro-6,7-dihydroxyisoquinoline

(1R,3S,1'S)-1-{[1'-(N-fluorenyl)methoxycarbonyl]amino}ethyl-3-methoxycarbonyl-1,2,3,4-tetrahydro-6,7-dihydroxyisoquinoline

B

(1S,3S,1'S)-1-{[1'-(N-fluorenyl)methoxycarbonyl]amino}ethyl-3-methoxycarbonyl-1,2,3,4-tetrahydro-6,7-dihydroxyisoquinoline

(1S,3S,1'S)-1-{[1'-(N-fluorenyl)methoxycarbonyl]amino}ethyl-3-methoxycarbonyl-1,2,3,4-tetrahydro-6,7-dihydroxyisoquinoline

C

(1S,3S)-1-[(S)-1-(9H-Fluoren-1-ylmethoxycarbonylamino)-ethyl]-7,8-dihydroxy-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid methyl ester

(1S,3S)-1-[(S)-1-(9H-Fluoren-1-ylmethoxycarbonylamino)-ethyl]-7,8-dihydroxy-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid methyl ester

D

(1R,3S)-1-[(S)-1-(9H-Fluoren-1-ylmethoxycarbonylamino)-ethyl]-7,8-dihydroxy-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid methyl ester

(1R,3S)-1-[(S)-1-(9H-Fluoren-1-ylmethoxycarbonylamino)-ethyl]-7,8-dihydroxy-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid methyl ester

Conditions
ConditionsYield
With trifluoroacetic acid In dichloromethane at 20℃; for 6h; Pictet-Spengler condensation;A 28%
B 23%
C n/a
D n/a
Fmoc-Phe-H

Fmoc-Phe-H

L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

A

(1S,3S,1'S)-1-{[1'-(N-fluorenyl)methoxycarbonyl]amino}phenylethyl-3-methoxycarbonyl-1,2,3,4-tetrahydro-6,7-dihydroxyisoquinoline

(1S,3S,1'S)-1-{[1'-(N-fluorenyl)methoxycarbonyl]amino}phenylethyl-3-methoxycarbonyl-1,2,3,4-tetrahydro-6,7-dihydroxyisoquinoline

B

(1R,3S,1'S)-1-{[1'-(N-fluorenyl)methoxycarbonyl]amino}phenylethyl-3-methoxycarbonyl-1,2,3,4-tetrahydro-6,7-dihydroxyisoquinoline

(1R,3S,1'S)-1-{[1'-(N-fluorenyl)methoxycarbonyl]amino}phenylethyl-3-methoxycarbonyl-1,2,3,4-tetrahydro-6,7-dihydroxyisoquinoline

Conditions
ConditionsYield
With trifluoroacetic acid In dichloromethane at 20℃; for 6h; Pictet-Spengler condensation;A 25%
B 26%
3-(benzyloxycarbonylamino)propanoic acid
2304-94-1

3-(benzyloxycarbonylamino)propanoic acid

L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

β-alanyl-L-dopa
21612-39-5

β-alanyl-L-dopa

Conditions
ConditionsYield
(i) Et3N, POCl3, (ii) aq. NaOH, (iii) H2, Pd-C; Multistep reaction;
3-(4-iodophenyl)propionic acid
1643-29-4

3-(4-iodophenyl)propionic acid

L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

(S)-3-(3,4-Dihydroxy-phenyl)-2-[3-(4-iodo-phenyl)-propionylamino]-propionic acid methyl ester
132513-20-3

(S)-3-(3,4-Dihydroxy-phenyl)-2-[3-(4-iodo-phenyl)-propionylamino]-propionic acid methyl ester

Conditions
ConditionsYield
With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In N,N-dimethyl-formamide
L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

sodium 3-(4-methoxyphenyl)oxiran-2-carboxylate
84382-48-9

sodium 3-(4-methoxyphenyl)oxiran-2-carboxylate

(1S,3S)-6,7-Dihydroxy-1-(4-methoxy-benzyl)-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid methyl ester
133761-45-2, 133761-46-3

(1S,3S)-6,7-Dihydroxy-1-(4-methoxy-benzyl)-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid methyl ester

(1S,3R)-6,7-Dihydroxy-1-(4-methoxy-benzyl)-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid methyl ester
133761-45-2, 133761-46-3

(1S,3R)-6,7-Dihydroxy-1-(4-methoxy-benzyl)-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid methyl ester

Conditions
ConditionsYield
With acetic acid In water at 35℃; for 36h;A 145 mg
B 45 mg
L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

levodopa
59-92-7

levodopa

Conditions
ConditionsYield
With water; sodium chloride In dimethyl sulfoxide at 37℃; Rate constant; also human plasma as reagent;
With sodium carbonate In acetonitrile for 15h;
With potassium hydroxide In methanol
L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

3-(4-fluoro-3-nitrophenyl)propanoic acid
160877-40-7

3-(4-fluoro-3-nitrophenyl)propanoic acid

(2S)-methyl 3-(3,4-dihydroxyphenyl)-2-[3-(4-fluoro-3-nitrophenyl)propionylamino]propionate
203310-99-0

(2S)-methyl 3-(3,4-dihydroxyphenyl)-2-[3-(4-fluoro-3-nitrophenyl)propionylamino]propionate

Conditions
ConditionsYield
With 1.) TMS-X Yield given. Multistep reaction;
L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

(R)-N-(tert-butoxycarbonyl)-4-fluoro-3-nitrophenylalanine
173775-54-7

(R)-N-(tert-butoxycarbonyl)-4-fluoro-3-nitrophenylalanine

methyl N-[N-(tert-butyloxycarbonyl)-L-(3,4-dihydroxyphenylalanyl)]-D-4-fluoro-3-nitrophenylalaninate
203311-03-9

methyl N-[N-(tert-butyloxycarbonyl)-L-(3,4-dihydroxyphenylalanyl)]-D-4-fluoro-3-nitrophenylalaninate

Conditions
ConditionsYield
With 1.) TMS-X Yield given. Multistep reaction;
L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

(S)-N-(tert-butyloxycarbonyl)-4-fluoro-3-nitrophenylalanine

(S)-N-(tert-butyloxycarbonyl)-4-fluoro-3-nitrophenylalanine

methyl N-[N-(tert-butyloxycarbonyl)-L-(3,4-dihydroxyphenylalanyl)]-L-4-fluoro-3-nitrophenylalanine
203311-01-7

methyl N-[N-(tert-butyloxycarbonyl)-L-(3,4-dihydroxyphenylalanyl)]-L-4-fluoro-3-nitrophenylalanine

Conditions
ConditionsYield
With 1.) TMS-X Yield given. Multistep reaction;
L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

L-dopachrome methyl ester

L-dopachrome methyl ester

Conditions
ConditionsYield
With sodium periodate In phosphate buffer for 0.166667h; pH=6.0; Oxidation; cyclization;
L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

acetyl chloride
75-36-5

acetyl chloride

2-amino-3-(3,4-diacetoxyphenyl)-propionic acid
39101-99-0

2-amino-3-(3,4-diacetoxyphenyl)-propionic acid

Conditions
ConditionsYield
With trifluoroacetic acid at 20℃;
L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

(S)-2-Amino-3-(3,4-dioxo-cyclohexa-1,5-dienyl)-propionic acid methyl ester

(S)-2-Amino-3-(3,4-dioxo-cyclohexa-1,5-dienyl)-propionic acid methyl ester

Conditions
ConditionsYield
With 3-methyl-2-benzothiazolinone hydrazone; (S)-(-)-1,1'-binapthyl-2,2-diamine copper(II) In methanol; phosphate buffer at 20℃; pH=8.6; Kinetics; Further Variations:; Catalysts;

7101-51-1Relevant articles and documents

Structural Transformative Antioxidants for Dual-Responsive Anti-Inflammatory Delivery and Photoacoustic Inflammation Imaging

Zhao, Caiyan,Chen, Jingxiao,Ye, Jiamin,Li, Zhi,Su, Lichao,Wang, Junqing,Zhang, Ye,Chen, Jinghua,Yang, Huanghao,Shi, Jinjun,Song, Jibin

supporting information, p. 14458 - 14466 (2021/05/13)

We have synthesized a PEGylated, phenylboronic acid modified L-DOPA pro-antioxidant (pPAD) that can self-assemble into nanoparticles (pPADN) for the loading of a model glucocorticoid dexamethasone (Dex) through 1,3-diol/phenylboronic acid chemistry and hydrophobic interactions for more effective treatment of inflammation. Upon exposure to ROS, pPADN convert into the active form of L-DOPA, and a cascade of oxidative reactions transform it into antioxidative melanin-like materials. Concomitantly, the structural transformation of pPADN triggers the specific release of Dex, along with the acidic pH of inflammatory tissue. In a rat model of osteoarthritis, Dex-loaded pPADN markedly mitigate synovial inflammation, suppress joint destruction and cartilage matrix degradation, with negligible in vivo toxicity. Moreover, in situ structural transformation makes pPADN suitable for noninvasive monitoring of therapeutic effects as a photoacoustic imaging contrast agent.

Easy access to drug building-blocks through benzylic C-H functionalization of phenolic ethers by photoredox catalysis

Brandhofer, Tobias,Derdau, Volker,García Manche?o, Olga,Méndez, María,P?verlein, Christoph,Stinglhamer, Martin

supporting information, p. 6756 - 6759 (2021/07/13)

A visible light-mediated photocatalyzed C-C-bond forming method for the benzylic C-H functionalization of phenolether containing synthetic building blocks based on a radical-cation/deprotonation strategy is reported. This method allows the mild, selective generation of benzyl radicals in phenolic complex molecules and drug-like compounds, providing new entries in synthetic and medicinal chemistry.

Small Molecule Inhibits Metal-Dependent and -Independent Multifaceted Toxicity of Alzheimer's Disease

Samanta, Sourav,Rajasekhar, Kolla,Babagond, Vardhaman,Govindaraju, Thimmaiah

, p. 3611 - 3621 (2019/09/10)

Alzheimer's disease (AD) is one of the most devastating forms of dementia, without reliable treatments to cure, delay the onset, or prevent the disease progression. The proposed toxic mechanisms of AD include amyloidogenesis of amyloid β (Aβ), metal ion dyshomeostasis, redox active metal-Aβ inclusion complex formation, and generation of excessive reactive oxygen and nitrogen species (ROS and RNS). The imbalance in redox homeostasis causes oxidative stress, DNA damage, mitochondrial dysfunction, and inflammation, which collectively become a major hurdle in the development of effective therapeutic agents for multifactorial AD. This necessitates a multifunctional strategy to develop effective therapeutic agents to inhibit multifaceted toxicity. In this context, we report a rational design, synthesis, and detailed study to identify a small molecule multifunctional modulator (MFM) inspired by the human origin tripeptide. The lead, MFM 4, chelates and sequesters metal ions, disrupts their redox cycles, prevents excessive ROS production and oxidative stress, ameliorates oxidative DNA damage and mitochondrial dysfunction, and modulates Nrf2 protein signaling under oxidative stress conditions by eliminating the toxic stress elements. The MFM 4 was found to inhibit metal-dependent and -independent Aβ aggregation and qualified as a suitable candidate to inhibit Aβ-induced neuronal toxicity. The NMR spectroscopy study revealed molecular-level interactions of 4 with Aβ42, which explain the mechanism of aggregation inhibition. Furthermore, 4 effectively inhibited inflammation as revealed by reduction in nitric oxide (NO) production in LPS-activated glial cells. These key features make 4 a potential MFM platform to develop therapeutic agents for metal (Cu, Zn and Fe)-dependent and -independent multifaceted Aβ toxicity of AD.

Water-soluble L-DOPA esters

-

Paragraph 0082, (2018/05/24)

The present invention relates to novel compounds of the formula I, methods for their preparation and their use for treatment of diseases. The invention discloses the synthesis of levodopa (L-DOPA) esters by coupling polyhydroxy compounds or their derivatives to the L-DOPA carboxyl group. The synthesis allows to produce L-DOPA derivatives which are highly soluble in water as well as aqueous and biocompatible liquids and have an improved hydrolytic stability in water or aqueous and biocompatible media for an application over several days. The invention helps producing L-DOPA substances for applications in the fields of medicine, biology and medical engineering as well as in the pharmaceutical industry.

Base/Cryptand/Metal-Free Automated Nucleophilic Radiofluorination of [18F]FDOPA from Iodonium Salts: Importance of Hydrogen Carbonate Counterion

Maisonial-Besset, Aurélie,Serre, Audrey,Ouadi, Ali,Schmitt, Sébastien,Canitrot, Damien,Léal, Fernand,Miot-Noirault, Elisabeth,Brasse, David,Marchand, Patrice,Chezal, Jean-Michel

supporting information, p. 7058 - 7065 (2019/01/04)

As evidenced by the number of publications and patents published in the last years, the radiosynthesis of 6-[18F]fluoro-3,4-dihydroxy-L-phenylalanine ([18F]FDOPA) using the nucleophilic [18F]F- process remains currently a challenge for the radiochemists scientific community even if promising methods for the radiofluorination of electron-rich aromatic structures were recently developed from arylboronate, arylstannane or iodonium salt precursors. In such context, based on the use of an iodonium triflate salt precursor, we optimized a fast and efficient radiofluorination route fully automated and free from any base, cryptand or metal catalyst for the radiosynthesis of [18F]FDOPA. Using this method, this clinically relevant radiotracer was produced in 64 min, 27–38 % RCY d.c. (n = 5), >99 % RCP, >99 % ee., and high Am 170–230 GBq/μmol. In addition, this optimization study clearly highlighted the important role of a triflate-hydrogen carbonate counterion exchange during the radiolabeling process to achieve high fluorine-18 incorporation yields.

A self-assembled tetrapeptide that acts as a “turn-on” fluorescent sensor for Hg2+ ion

Tomar, Kalpana,Kaur, Gagandeep,Verma, Sandeep,Ramanathan, Gurunath

supporting information, p. 3653 - 3656 (2018/09/11)

The tetrapeptide (Bz-ΔPhe(p-NPh2)-L-DOPA(protected)-L-Phe-L-Phe-OMe was designed to incorporate seven phenyl rings so that it's conformation, self-assembly and application in Hg2+ ions sensing could be studied. Peptide molecules adopted an overlapping β-turn of type III/III conformation in crystals. The peptide showed a highly selective turn-on response towards mercuric ion over other metal ions with a 10-fold enhancement in fluorescence intensity. This intensity change coupled with the selectivity of the peptide towards mercury allowed us to demonstrate simple colorimetric dip sensing of Hg2+ ions. The technique provides a highly selective and effective way to detect Hg2+ ions. The peptide also self-assembled into nanospheres with diameter ranges from 100 to 500 nm. Mercuric ion coordination enabled these peptide nanospheres to aggregate into well-defined nanoparticles. The enhanced fluorescence upon Hg2+ addition demonstrates that peptide scaffolds can be exploited in the development of different selective sensors.

Synthesis and cytotoxicity of dinuclear platinum(II) complexes of (1S, 3S)-1,2,3,4-tetrahydroisoquinolines

Xu, Geng,Guo, Ju,Yan, Zheng,Wang, Nan,Liu, Zhan-Zhu

, p. 186 - 188 (2013/06/26)

A series of novel dinuclear platinum(II) complexes with (1S, 3S)-1,2,3,4-tetrahydroisoquinolines as the ligands were synthesized as potential anticancer agents in several steps starting from commercially available l-DOPA. The cytotoxicities of the series of dinuclear platinum(II) complexes of tetrahydroisoquinoline were tested against HCT-8, BEL-7402, A2780, MCF-7, Hela, A549 and BGC-823 cell lines by the MTT test. These complexes showed selective inhibition activity against cisplatin-insensitive cell line Skov3.

Total synthesis of pyoverdin D

Mashiach, Roi,Meijler, Michael M.

supporting information, p. 1702 - 1705 (2013/06/27)

Pyoverdin D is an important siderophore that is used by the human pathogen Pseudomonas aeruginosa to import iron and gain a competitive advantage. This unique partially cyclic octapeptide bears four nonproteinogenic amino acids, including δN-formyl-δN-hydroxy-l-ornithine, and a catechol containing chiral chromophore. Here, we report the first total synthesis of pyoverdin D.

Synthesis of C-1 indol-3-yl substituted tetrahydroisoquinoline derivatives via a Pictet-Spengler approach

Larsson, Rikard,Blanco, Narda,Johansson, Martin,Sterner, Olov

supporting information, p. 4966 - 4970 (2012/11/07)

A protocol for the diastereoselective synthesis of C-1 indol-3-yl substituted tetrahydroisoquinoline derivatives via Pictet-Spengler condensation with L-DOPA or l-DOPA derivatives and 1H-indole-3-carbaldehydes is presented. The protocol is used for the successful synthesis of several tetrahydroisoquinolines as well as diketopiperazine fused analogues.

An Au(I)-catalysed allenamide cyclisation giving access to an α-vinyl-substituted tetrahydroisoquinoline building block

Singh, Sanjitpal,Elsegood, Mark R. J.,Kimber, Marc C.

scheme or table, p. 565 - 568 (2012/04/04)

An Au(I)-catalysed intramolecular hydroarylation of an enantiopure allenamide has been achieved and has given access to a key α-vinyl- substititued tetrahydroisoquinoline. Additionally this has been accomplished in very high yield and high diastereoselectivity. Georg Thieme Verlag Stuttgart · New York.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 7101-51-1